Introducing 428Pharma.
Developing the world's first treatment to prevent relapse in depression
Why preventing relapse matters
After their first episode of depression, 1 in 2 patients will relapse.
With each new episode, the risk grows — to 70% after the second and 90% after the third.
Once a patient experiences two or more relapses, they are classified as having Treatment-Resistant Depression (TRD) — a severe form of the disease that is much harder to treat.
Tragically, up to 30% of TRD patients attempt suicide during their lifetime.
Between 2007 and 2017, the suicide death rate among young people (ages 10–24) rose by 56%.
At 428 Pharma, we believe prevention is the most powerful form of treatment.
By preventing relapse, we can stop depression from progressing to treatment resistance — and ultimately, help save lives.
Today, no approved therapies exist that effectively prevent relapse in Major Depressive Disorder (MDD).
We’re changing that.
Our Product
Escitalopram LAI (Long Acting Injectable)
428 Pharma develops a formulation of the worlds first LAI for prevention of relapse in MDD with a potential time to market 2028
-
First depot injection for SSRI for a vast depression market estimated at $15.8Bn in 2025
-
505(b)(2) truncated development with LOE 2046. PK only approval pathway under FDA
-
Opportunity to out-license end of phase I